119 results about "Clopidogrel Bisulfate" patented technology

Pharmaceutical tablets comprising clopidogrel bisulfate and a lubricant selected from zinc stearate, stearic acid, and sodium stearyl fumarate.

The present invention relates to new polymorphs of S-(+)-Clopidogrel bisulfate and a process for preparing the same.

The invention provides two methods for synthesizing Clopidogrel sulfate of single I crystal system, wherein the first method starts from indefinite form Clopidogrel sulfate, and the second method starts from Clopidogrel salts.

The invention discloses an improved preparation method of a II-type clopidogrel hydrogen sulfate crystal, which is an improvement of the existing II-type clopidogrel hydrogen sulfate crystal form preparation technique. The method greatly enhances the yield on the premise of ensuring the product appearance (the average yield is up to 92%), and prepares the product with better appearance on the premise of obviously enhancing the product yield.

The invention relates to a clopidogrel bisulfate tablet and a preparation method thereof. Each clopidogrel bisulfate tablet comprises 25-75 mg of clopidogrel bisulfate measured in the term of clopidogre, fillers, disintegrants, solubilizers, flow aids and lubricants. In the invention, the method of adding granular microcrystalline cellulose and aerosil through airflow crushing disposal to a prescription is adopted, therefore, the process of dry granulating is simple and feasible, reproducibility is good, prepared products have high stability, and the requirement of continuous large-scale production can be satisfied.

The invention relates to a method for producing sulfuric acid chlorogray of styleó±, containing the following steps: under the protection of inert gas and cooled with iced water, adding aqueous solution with sodium carbonate/ potassium into organic solvent comprising chlorogray salt until the pH is higher than 9; and demixing the liquid, extracting the water layer with the same organic solvent, after combining with organic phase, drying and concentrating it to get free chlorogray alkali; then dissolving it in solvent, dropping in stoichiometric sulfate liquor, and the chlorogray formed, with the temperature controlled between minus 20 Deg.C to 5 Deg.C; then filtering the mixed solution, vacuum drying it, and then the sulfuric acid chlorogray of styleó±can be collected. The sulfuric acid chlorogray produced in such way is proved to beó±morph crystal system confirmed by X-ray diffraction, infrared spectrum and DSC spectrogram, and the fusible point is 181~186 Deg.C, and the specific rotation is 52.0í½55.0 deg. (c=1, carbinol). The method can produce sulfuric acid chlorogray of styleó±steadly.

The invention provides improved processes for the preparation of hydrated form of (S)-(+)-Clopidogrel bisulfate as well as improved processes for the preparation of form-I and form-II of (S)-(+)-Clopidogrel bisulfate.

The invention discloses clopidogrel bisulfate crystal particles with the median particle diameter of at least 120 microns. The invention also discloses a method for preparing the crystal particles, a pharmaceutical composition containing the crystal particles and a preparation method of the pharmaceutical composition.

This invention relates to pharmaceutical tablet formulations of clopidogrel bisulphate which include glyceryl dibehenate as lubricant. The tablets are found to be very stable and to exhibit suitable dissolution characteristics.

Linking Magnesium ions to Nitric Oxide precursor L-Arginine, chemically 2-amino-5-guanidino valeric acid, with a platelet aggregation inhibitor compound such as, but not limited to acetylsalicylic acid or clopidogrel bisulfate, unexpectedly results in a pharmaceutically stabilized compositions with extended shelf life to be taken orally to provide gradual release vasodilatory and anti-platelet aggregation pharmacological activity with reduced potential for producing gastrointestinal lesions. L-Arginine releases ADNO (Arginine derived Nitric Oxide) in the coronary artery epithelium as EDRF (endothelium dependent relaxing factor) to dilate the arteries to promote blood flow to the myocardium, and the platelet aggregation inhibitor such acetylsalicylic acid or clopidogrel and others of this class of drugs inhibits or antagonizes the aggregation adhesion of platelets in the blood stream. Aggregated or clumped blood platelets contribute to arterial stenosis due to formation of atherosclerotic plaques that occlude coronary and other circulatory arteries. In addition to coronary arteries, atherosclerotic plaques can occlude and stenose carotid arteries and femoral arteries due to aggregated or clumped blood platelets, and the subject of this patent discovery will also be of cardiovascular health benefit respectively in preventing carotid cerebrovascular accidents and femoral artery leg circulation disease.

The invention relates to a method for preparing a related substance B in a platelet aggregation inhibition medicament-clopidogrel bisulfate. The method comprises the steps of: adopting dienone and L-2-chlorophenylglycine methyl ester to obtain tetrahydropyridone through a closed-loop reaction; then obtaining a 2-aminothienopyridine derivative through a Gewald reaction; and finally obtaining a target product through diazotization and acid hydrolysis. The process takes the synthesis of a pyridine ring first and then the synthesis of a thiophene ring as a route, obtains the target product with higher yield through a classical reaction, and provides novel thought for the synthesis of the related substance B of the clopidogrel bisulfate.

The invention relates to a preparation method of a drug compound, in particular to a preparation method of clopidogrel hydrogen sulfate I. The method provided by the invention comprises the following steps: 1, mixing clopidogrel salt with an organic solvent and water, adding an acid binding agent to react to generate free alkali of clopidogrel, extracting the water layer with the organic solvent, combining the organic phases and carrying out concentration; and 2. adding the organic solvent into the free alkali of clopidogrel obtained after concentration, dropwise adding sulfuric acid into the solution for reaction based on the molar ratio of the sulfuric acid to the free alkali of clopidogrel, filtering the reactant and drying the filtrate to obtain the crystal form of clopidogrel hydrogen sulfate I, wherein the molar ratio is (0.8-1.05):1.

The invention discloses a synthesis method of high-purity I-type (+)-(S)-clopidogrel hydrogen sulfate, which comprises the following steps: 1) mixing an acetone solution of L(-)-camphorsulfonic acid and an acetone solution of (+)-(S)-clopidogrel crude product to carry out salification reaction for 6-10, filtering after the reaction finishes, and treating the filter cake to obtain (+)-(S)-clopidogrel L(-)-camphorsulfonate; 2) dissolving the product obtained in the step 1) in a mixture of dichloromethane or ethyl acetate and water, regulating the pH value to 7-8, stirring for 10-60 minutes, standing to stratify, and treating the organic layer to obtain a (+)-(S)-clopidogrel pure product; and 3) dissolving the product obtained in the step 2) in an organic solvent, adding a crystal seed, stirring, adding an organic solvent solution of sulfuric acid, heating to 50-60 DEG C, stirring for 1-3 hours, cooling to room temperature, filtering, and treating the filter cake to obtain the high-purity I-type (+)-(S)-clopidogrel hydrogen sulfate. The method has the advantages of simple technique, high product yield and high product purity, and is suitable for industrial production.

The invention relates to a production technique of clopidogrel hydrogen sulfate, which comprises the following steps: (1) preparation of amide hydrochloride, (2) preparation of levo-camphorsulfonate, (3) preparation of clopidogrel hydrogen sulfate crude product and (4) preparation of I-type clopidogrel hydrogen sulfate. The technique is simple, reduces the synthesis steps, lowers the consumption of toxic solvents, enhances the drug safety, facilitates the recovery and treatment of the waste liquid and lowers the production cost. The purity of the clopidogrel hydrogen sulfate obtained by the method is high, and the yield is 6.5% higher than other methods.

The invention provides pharmaceutical composition containing spherical clopidogrel bisulfate I crystal form and a preparation method of the pharmaceutical composition. Direct powder compressing can be achieved favorably by the powder property of the pharmaceutical composition, and sticking during tablet compressing is avoided. The invention further provides a clopidogrel bisulfate tablet using direct powder compressing and a preparation method of the tablet. The tablet meets the requirements of clinical medication.

The invention discloses a method for determining the content of dimethyl sulfate in clopidogrel hydrogen sulfate, and belongs to the technical field of medicines. The method adopts a gas chromatograph-mass spectrometer to determine the content of dimethyl sulfate in clopidogrel hydrogen sulfate, and comprises the following steps: firstly, preparing a test solution, and storing the prepared solution in an environment below 0 DEG C for later use; then setting detection conditions of a gas chromatograph-mass spectrometer; after the sample introduction condition is met, starting sample introduction, completing the detection process, and rcording a chromatogram. The method for detecting the dimethyl sulfate in the clopidogrel hydrogen sulfate is high in detection sensitivity, the linear range of the dimethyl sulfate is within the range of 5%-500% of the limit concentration, and the linear relation between the concentration and the peak area is good. According to recovery rate, repeatabilityand sample injection precision tests, the precision and accuracy of the method are good. A reference substance solution stability test shows that the reference substance solution has good stability after being placed at 0 DEG C or below for 6 hours.

The invention discloses a type I clopidogrel hydrogen sulfate salt preparation method which comprises the following steps: (1) mixing clopidogrel salt with an organic solvent, adding water, adding an acid binding agent or an acid binding agent water solution to the solvent, stirring for reaction to generate clopidogrel free alkali, standing for layering, extracting aqueous phase with the same organic solvent, combining the organic phase, washing with water, recovering the solvent to dry; and (2) adding an organic solvent into the concentrated clopidogrel free alkali, stirring to fully dissolve the clopidogrel free alkali, cooling, adding seed crystal, according to the molar ratio of sulfuric acid to clopidogrel free alkali of 0.9-1.05:1, dropwise adding sulfuric acid solution into the solution, standing, filtering, and drying to obtain the type I clopidogrel hydrogen sulfate. The type I clopidogrel hydrogen sulfate obtained by the method has the advantages of high purity and stable property.

The invention provides a crystal form of a compound as shown in the formula II. The crystal form belongs to an orthorhombic crystal system; the space group is P212121; the crystal cell parameters are as shown in the specification, wherein alpha is equal to 90.00 DEG, beta is equal to 99.00 DEG, and gamma is equal to 90.00 DEG; Z is equal to 4; the crystal cell volume is as shown in the specification. The invention also provides a preparation method and application of the crystal form. The compound with the crystal form in the formula II, which is separated from leonurus japonicus, has a certain inhibiting effect on platelet aggregation and has a better effect than clopidogrel bisulfate as an anti-platelet aggregation drug under the same concentration (0.1mM), so that a new choice is provided for developing a novel natural anti-platelet aggregation drug.

The invention provides a method for preparing a crystalline form I of clopidogrel bisulfate. The method is characterized by comprising a step of dissolving raw materials of a clopidogrel bisulfate crystal form product into an organic solvent methanol or ethanol; a step of adding, in a temperature range of -30 DEG C to 30 DEG C, the dissolved and clarified solution into a mixed solution of an acid and an anti-solvent; a step of stirring uniformly and centrifuging for 3-60 min; and a step of drying the centrifugation product, after the centrifugation product is washed with the anti-solvent, to obtain the stable crystalline form I powder of the clopidogrel bisulfate. The product of the method is an aggregation of tetragonal-structured crystals, and has good stability. The method has simple operation, suitability for industrial production, capability of environmental protection, high product purity and high yield.

The invention relates to a preparation method of clopidogrel and an intermediate of clopidogrel. The preparation method comprises the following steps: using L-2-chlorophenylglycine as a starting raw material, firstly taking reaction to L-2-chlorophenylglycine with methanol to generate L-2-chlorophenylglycine methyl ester, then using L-(+)-tartaric acid to split L-2-chlorophenylglycine methyl ester to obtain S-(+)-chlorophenylglycine methyl ester and L-(+)-tartrate, taking reaction to the split product with 2-(2-thienyl)-ethanol-p-toluenesulfonate to obtain 2-chlorophenyl-2-thienylethylamine methyl acetate hydrochloride, taking reaction with formaldehyde to close ring to obtain clopidogrel, and carrying out acidification with sulfuric acid to obtain clopidogrel hydrosulfate. The provided synthetic method is simple in route, high in yield, low in cost, and simple to operate. The method for preparing clopidogrel and the intermediate of clopidogrel is easy to industrially produce. During the test process, the method is free from special, toxic and harmful reagents, and beneficial to environment protection. The synthetic process can be operated at normal temperature; the reaction conditions are mild; the processing equipment is simple; the method is easy to realize industrialized production.

A solid formulation of clopidogrel bisulfate and its preparation method are disclosed. The formulation comprises clopidogrel bisulfate as active ingredient, colloidal silicon dioxide as anti-adherent/coating and the carriers selected from diluent, binder, glidant, disintegrant and/or lubricant.

The invention relates to a preparation method of a clopidogrel bisulfate solid preparation. The method discloses a two-step granulation process of melt-granulating and then dry-pressing granulating for clopidogrel bisulfate, and the obtained granules have good compressibility and fluidity, and are not easy to stick to a die, so that the problems of tablet sticking, easy revealing or splitting which are common in the preparation of oral tablets of clopidogrel bisulfate is solved. The preparation method can ensure the rapid dissolution of the drug in the preparation, and the long-term retentionof the sample does not increase the impurities. The preparation process of the present invention is highly practical and can be used for large-scale preparation of clopidogrel sulfate bulk drugs withdifferent physical properties.